What Alpha-Beta learned in trial

Angry investors hammered Alpha-Beta Technology Inc. stock amid concerns over the company's timeline for entering Phase III studies of Betafectin and following an unfriendly reception to the presentation of its second Phase I/II study at the Surgical Infection Society meeting in Toronto.

But in retrospect, the problem with the data started in early April, when ABTI released the abstract for the meeting. The abstract raised more questions than it answered, specifically why the placebo and 0.1 mg/kg doses were grouped together and why the 0.5, 1 and 2 mg/kg doses were grouped. In addition, as a result of the grouping, it wasn't possible to determine whether there was a dose response...